The discovery of F1-ATPase and P2Y13 receptor (P2Y13r) in the liver, which regulates the elimination of HDL-C, improved the understanding of HDL metabolism and opened new pathways for the development of therapeutic approaches. The P2Y13 receptor belongs to the well-known family of P2Y receptors including the P2Y12 receptor, the target of successful drugs such as the anti-thrombotic agent Clopidogrel (Plavix®).

CER-209 is the first drug candidate in its class, oral P2Y13 receptor agonists.

Preclinical studies have shown that CER 209 acts on the last step of the RLT pathway, increasing HDL recognition by the liver and facilitating the elimination of lipids in the faeces, ultimately leading to a regression of atherosclerotic plaque.  

Because of the favorable metabolic effects observed in the liver in preclinical experiments, CER 209 may also offer a new mechanism for the treatment of atherosclerois and of non-alcoholic steato-hepatitis (NASH).